Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 1 EP application Richard Lewis Easeman has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 18, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12700019

LIGANDS THAT BIND TGF-BETA RECEPTOR II

IPC classification:
C07K 16/28
Applicant:
Glaxo Group Limited
Agent:
Richard Lewis Easeman, GlaxoSmithKline
Status:
PATENT GRANTED

Please Sign in to use this feature